PEPTIDE

Safety

Research Trial Design and Safety Reporting

How to evaluate the quality of human trials and safety reporting in peptide research.

Last updated: 10 April 2026

Elements of good trial design

Randomization: random assignment to treatment and control groups reduces selection bias. Blinding: participants and researchers not knowing who receives treatment reduces expectancy bias. Sample size: larger samples produce more reliable results.

Placebo controls: necessary to distinguish treatment effects from natural improvement or placebo response.

Adverse event monitoring and reporting

Good trials have systematic processes for: identifying adverse events, documenting severity and relationship to the treatment, and monitoring stop criteria (if an event is severe, halt the trial).

Look for clear reporting of how many participants experienced what events at what severity.

Trial design red flags

No control group. No mention of adverse events. Very small sample size (<20). Funding only by manufacturer. Published only in non-peer-reviewed sources. Researchers with undisclosed conflicts.

How to evaluate a trial

Read the methods section. Was it randomized and blinded? What was the sample size? How long did it last? Read the results: what primary outcomes changed? Were adverse events documented and reported transparently?

A well-designed trial with small effects is more credible than a poorly-designed trial with large effects.

Frequently asked questions

Good trial design, larger sample size, longer duration, independent funding, transparent adverse-event reporting, and replication by other groups.